Special Report - The Autism Spectrum Disorders Market: Substantial Opportunity and Unique Challenges

Published by	Decision Resources, Inc.
Published	August, 2009	Product code	98425
Content info	28 Pages
Price	US $ 6900 PDF by E-mail (Global License)

Introduction
Related Reports

Special Report - The Autism Spectrum Disorders Market: Substantial Opportunity and Unique Challenges published by Decision Resources, Inc. in August, 2009. This report consists of 28 Pages and the price starts from US $ 6900.

Introduction

Abstract

Introduction

An increase in public funding for research and a heightened interest among drug developers suggest that a breakthrough in autism spectrum disorder (ASD) treatment may be imminent. However, drug development has been slow, plagued by a limited understanding of the disease and the difficulties in developing treatments for pediatric populations in general and in ASD in particular. However, substantial opportunity exists for an agent that can safely improve an autistic child' s ability to interact and adapt to his or her surroundings.

Questions Answered in This Report

ASD includes three distinct diagnoses: Asperger' s disorder, classic aut ism, and pervasive development disorder - not otherwise specified. What are the common symptoms in these disorders? How do they differ from one another? What is known about the cause of the disease?
Public awareness of ASD has increased substantially over the last ten years, and Decision Resources has conducted a comprehensive review of the epidemiology of this indication. How many children in the United States are diagnosed with ASD? How will this population grow over the next ten years? How is ASD diagnosed?
Janssen' s Risperdal is the only agent approved for the treatment of ASD. What are the goals of drug treatment in ASD? How effective are current therapies? What is the potential of emerging agents?
One interviewed thought leader treating ASD characterizes current treatments as "throwing a dart at the board." What do thought leaders say about emerging approaches? Why does glutamate excitotoxicity particularly intrigue them? What treatment challenges and needs do they identify?

Scope

Overview of ASD: Disease description and symptoms, etiology, diagnosis.
Epidemiology: Prevalent cases of ASD in the United States, forecasted prevalence to 2018, evaluation of trends in ASD prevalence.
Primary research: Interviews with thought-leading specialists treating ASD as well as their opinions on current and emerging agents and treatment dynamics.
Current treatments: Atypical antipsychotics, antidepressants, stimulants, antiepileptics, complementary and alternative medicine (CAM).
Emerging treatments: Forest Laboratories/Merz' s Namenda (memantine), BioMarin' s Kuvan, Seaside Therapeutics' STX-209, Curemark' s CM-AT. Outlook: 2008 major-market (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) sales, potential of emerging agents.

Mentioned in This Report

Companies

Abbott
AstraZeneca
BioMarin Pharmaceutical
Boehringer Ingelheim
Bristol-Myers Squibb
Curemark
Eli Lilly
Forest Laboratories
GlaxoSmithKline
Janssen
Janssen-Cilag
Lundbeck
McNeil Pediatrics
MDRNA
Merz
Neuropharm
Novartis
Ortho-McNeil
Otsuka Pharmaceutical
Pfizer
Seaside Therapeutics
Shire

Executive Summary
- Strategic Considerations
- Stakeholder Implications
Introduction
Overview of Autism Spectrum Disorders
- Disease Definitions and Symptoms
- Etiology
- Diagnosis
Epidemiology
- Overview
- Disease Definition
- Methods
- Prevalence Trends
- Subpopulations
Treatment Approaches for Autistic Spectrum Disorder
- Atypical Antipsychotics
- Serotonin Reuptake Inhibitors
- Stimulants
- Other Drug Treatments
Emerging Treatments for Autism Spectrum Disorders
- Forest Laboratories/Merz' s Memantine
- BioMarin' s Kuvan
- Seaside Therapeutics' STX-209
- Curemark' s CM-AT
Market Outlook
Appendix A. Bibliography
Appendix B. Physicians and Researchers Interviewed - Autism